In mid-September 2026, the U.S. Food and Drug Administration (FDA) classified a nationwide recall of chlorthalidone tablets (25 mg) manufactured by Inventia Healthcare Limited as a Class II recall. The action followed quality testing indicating that specific lots failed dissolution specifications. For millions of Americans taking chlorthalidone daily to control high blood pressure, news of a prescription recall naturally raises urgent questions.
Understanding dissolution failure provides vital perspective. Unlike contamination events involving toxic impurities, a dissolution failure means the physical tablet does not break down at the expected rate in the digestive tract. The primary clinical risk is subtherapeutic drug absorption—leaving hypertension insufficiently controlled. Crucially, cardiovascular specialists emphasize that patients should never stop taking blood pressure medication abruptly, as sudden cessation can trigger severe rebound blood pressure spikes.
What the FDA Chlorthalidone Recall Involves
According to the official U.S. Food and Drug Administration (FDA) Enforcement Reports Database, Inventia Healthcare Limited voluntarily initiated the recall on September 3, 2026, and the FDA classified it as a Class II recall on September 17, 2026. The recall covers 13,567 bottles of 100-count Chlorthalidone Tablets, USP, 25 mg, distributed across the United States.
Under federal regulations, the FDA defines a Class II recall as a situation where exposure to a violative product may cause temporary or medically reversible adverse consequences, or where the probability of serious adverse harm is remote. This contrasts with a Class I recall, which indicates an imminent danger of serious injury or death. This represents the second recall for the manufacturer involving chlorthalidone dissolution issues in 2026, following a June action affecting batches RISA24001 and RISB24002.
The Science of Dissolution: Why Absorption Rates Matter
Solid oral medications must pass strict in vitro dissolution testing during commercial distribution. The FDA Center for Drug Evaluation and Research Dissolution Testing Guidance establishes acceptance criteria based on United States Pharmacopeia (USP) standards.
When a patient swallows a tablet, it must disintegrate in stomach fluids and dissolve completely so drug molecules can cross the intestinal lining into circulation. Dissolution baths simulate gastrointestinal motility and pH conditions at 37°C. When a tablet is pressed too tightly or excipients harden over shelf-life, dissolution slows down significantly. Pharmacologically, this causes:
- Subtherapeutic Bioavailability: The tablet passes through the upper small intestine without releasing its full dose, leading to low blood concentrations.
- Blunted Peak Levels: Maximum drug concentrations drop, undermining predictable vascular dilation and sodium excretion.
- Loss of 24-Hour Coverage: Chlorthalidone is valued for smooth blood pressure reduction; erratic dissolution leaves patients vulnerable to morning blood pressure surges.
Why Chlorthalidone Is a Preferred Antihypertensive
Chlorthalidone holds an established place in cardiovascular care. In the 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults, expert panels recommended chlorthalidone as a preferred first-line thiazide-like diuretic over hydrochlorothiazide.
This preference is driven by pharmacokinetics. Chlorthalidone has an elimination half-life of 40 to 60 hours, compared to 6 to 12 hours for hydrochlorothiazide. This prolonged duration provides continuous arterial dilation and buffers against swings in vascular resistance between daily doses.
Its clinical impact was demonstrated in the landmark ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), a randomized double-blind study of 33,357 hypertensive patients published in JAMA. In ALLHAT, chlorthalidone proved superior in preventing heart failure and equally effective at reducing fatal coronary events compared to newer medication classes. However, these benefits depend on consistent, fully absorbed doses. When a tablet fails to dissolve, that protective shield diminishes.
Recall Summary and Identification Details
The table below summarizes key manufacturing specifications and regulatory details for the affected product:
| Detail | Specification | Clinical Relevance |
|---|---|---|
| Product Name | Chlorthalidone Tablets, USP, 25 mg | First-line thiazide-like antihypertensive diuretic |
| Manufacturer | Inventia Healthcare Limited | Generic pharmaceutical producer |
| Batch Number | Batch No. RISA24002 | Check prescription label or manufacturer bottle |
| National Drug Code | NDC 64980-599-01 (100-count bottles) | FDA 10-digit product identifier |
| Expiration Date | April 2027 (04/2027) | Affected lot remains in active circulation |
| Classification | FDA Class II Recall (September 17, 2026) | Remote probability of severe adverse harm |
| Root Cause | Failed dissolution testing specifications | Slow tablet breakdown in digestive tract |
Sources: U.S. Food and Drug Administration (FDA) Enforcement Report and United States Pharmacopeia (USP) Dissolution Standards.
The Danger of Stopping Blood Pressure Medicine Abruptly
Upon hearing that a prescription has been recalled, a patient might consider stopping pills immediately. In cardiovascular pharmacology, however, abruptly stopping blood pressure medication is significantly more hazardous than finishing the bottle while arranging an exchange.
According to the National Heart, Lung, and Blood Institute (NHLBI) Treatment Guidelines, chronic diuretic therapy establishes a hemodynamic equilibrium. Sudden withdrawal can induce rebound hypertension, where blood pressure surges sharply above baseline levels within 24 to 72 hours. This acute spike poses substantial risks:
- Hypertensive Urgency: Blood pressure rising above 180/120 mm Hg, triggering severe headaches or dizziness.
- Cardiac Stress: Sudden vascular resistance increases that strain heart muscle and coronary arteries.
- Stroke Vulnerability: Rapid pressure fluctuations generate mechanical shear stress on cerebral blood vessels.
Action Plan: How to Check Your Prescription and Exchange It
If you take chlorthalidone, clinical pharmacists suggest following this checklist:
1. Check Your Medication Container
Examine your bottle. If you have the original manufacturer container, locate the NDC (64980-599-01) and verify whether the lot number reads RISA24002 with an expiration date of 04/2027. If dispensed in an amber pharmacy bottle, the label may list the manufacturer and lot. If that information is missing, contact your pharmacy.
2. Contact Your Dispensing Pharmacy
Call the pharmacy where your prescription was filled. Pharmacists record exact lot numbers in their dispensing software. A pharmacist can look up your history to determine whether your medication came from batch RISA24002. If so, they will replace your supply with tablets from an unaffected manufacturer or compliant batch at no additional charge.
3. Track Your Home Blood Pressure Readings
Take your blood pressure twice daily using a validated upper-arm cuff while awaiting an exchange. If your systolic readings consistently track 10 to 15 mm Hg above your typical controlled range, inform your prescribing healthcare provider.
4. Recognize Red-Flag Symptoms
Although Class II recalls carry a low likelihood of acute complications, warning symptoms require attention. Seek urgent medical evaluation if you experience severe shortness of breath, chest pressure, sudden weakness, or visual blurring.
Evidence Limitations and Clinical Context
Regulatory findings should be viewed in clinical perspective. In vitro dissolution tests are conducted under laboratory conditions using artificial fluids. While they correlate with human absorption, individual factors like gastric acid and meal timing also affect uptake. Taking a recalled tablet does not mean zero medication was absorbed.
Furthermore, this recall applies strictly to batch RISA24002 of 25 mg tablets from Inventia Healthcare Limited. Chlorthalidone formulations manufactured by other companies, as well as 50 mg strengths, remain compliant. Patients should always consult their healthcare provider before modifying any aspect of their cardiovascular regimen.
Related Reading
- Bodyweight Intervals vs. Slow Breathing for High Blood Pressure
- Prescribing Cascades in Older Adults: 24 Problem Sequences
- Intensive Blood Pressure Control Cuts Dementia Risk 15%
Sources and Further Reading
- U.S. Food and Drug Administration (FDA) Enforcement Reports Database
- FDA Center for Drug Evaluation and Research: Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Forms
- 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Chlorthalidone (ALLHAT Collaborative Research Group, JAMA 2002)
- National Heart, Lung, and Blood Institute (NHLBI): High Blood Pressure Treatment and Management
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.